[1000 osteoarthrosis patients in treatment with GGGs: an assessment of joint pain].
The analgesic activity of a chondroprotective agent--galactosamineglucuronoglycan sulphate (Condral) was evaluated in the course of an open investigation in a large number of outpatients attending the Istituto Emilio Bruzzone of Genoa or related Centres. Out of 1720 outpatients seen, 1000 were treated for 2 years with 800-1200 mg daily of GGG in one single administration (2-3 sachets or capsules of 400 mg) By the results obtained GGG was shown to have analgesic activity in a large number of cases. Tolerance of the treatment was good and no significant clinical side effects were ever observed.
Monteforte
P
P
DIMI, Cattedra di Reumatologia, Università degli Studi, Genova.
Guglielmi
L
L
Innocenti
M
M
Rovetta
G
G
D018712:Analgesics, Non-Narcotic / Q000009:adverse effects / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D005260:Female; D006025:Glycosaminoglycans / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000000981:diagnostic imaging / Q000188:drug therapy*; D010147:Pain Measurement; D011859:Radiography; D013997:Time Factors
D018712:Analgesics, Non-Narcotic; D006025:Glycosaminoglycans; C080839:galactosamine glucuronoglycan sulfate
1000 pazienti osteoartrosici in trattamento con GGGs: valutazione del dolore articolare.